Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 573, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ijpharm.2019.118736
Keywords
NLGplatin; Calreticulin; IDO inhibitor; Immunotherapy; Oxaliplatin
Categories
Funding
- National Science and Technology Major Project [2017YFA0205400]
- National Natural Science Foundation of China [81773667, 81573369]
- NSFC Projects of International Cooperation and Exchanges [81811540416]
- Fundamental Research Funds for the Central Universities [2632018PT01, 2632018ZD12]
- Firstclass Project [CPU2018GY06]
- 111 Project from the Ministry of Education of China
- State Administration of Foreign Experts Affairs of China [B16046]
Ask authors/readers for more resources
Oxaliplatin is a chemotherapeutic agent widely used in cancer treatment whereas its immunosuppressive effect hinders the progress of immunotherapy. Here we have synthesized a new compound NLGplatin constructed by combining oxaliplatin (OXA) and indoleamine 2,3-dioxygenase (IDO) inhibitor NLG919. The NLGplatin acquires chemotherapeutic properties of OXA and can activate the immune system, and also retains the ability to inhibit IDO enzyme activity without affecting the proliferation of immune cells. This difunctional drug has a great potential to achieve effective cancer chemoimmunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
